Exagen Inc. Engages with Investors Through Upcoming Conferences
Exagen Inc. (Nasdaq: XGN), recognized for its expertise in autoimmune testing, is excited to share details about its participation in several noteworthy investor conferences. This engagement not only demonstrates Exagen's commitment to transparency but also highlights its dedication to advancing the field of autoimmune diagnostics.
Key Investor Conference Participation
The company will be showcasing its innovations at the prestigious 16th Annual Craig-Hallum Alpha Select Conference. This event is scheduled for November 18, 2025. It's a renowned opportunity for investors to learn more about Exagen's impact on autoimmune disease diagnostics and decision-making.
Another Important Appearance
Following this, Exagen will also participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on November 20, 2025. This forum focuses on medical technology advancements and presents an excellent platform for Exagen to present its advancements and initiatives in autoimmune disease testing.
Understanding Exagen Inc.
Exagen Inc. is committed to excellence in the domain of autoimmune diagnostics, aimed at improving patient outcomes through innovative testing solutions. Their flagship product, AVISE CTD, plays a crucial role in diagnosing complex autoimmune conditions like lupus and rheumatoid arthritis with precision. This test not only aids in early diagnosis but also delivers results that enhance clinical decision-making.
Innovative Testing and Results
With their CLIA-certified and CAP-accredited laboratory, Exagen assures a high standard in the testing of rheumatic diseases. The company’s suite of AVISE-branded tests is comprehensive, covering diagnosis, prognosis, and ongoing monitoring of autoimmune conditions. Exagen’s strength lies in its ability to provide timely and accurate results, significantly impacting the patient's journey and outcome.
Commitment to Research and Innovation
Exagen's mission is grounded in a commitment to research, innovation, and education about autoimmune diseases. The dedicated team focuses on addressing the persistent challenges these conditions pose to patients and healthcare providers alike. By fostering an understanding and providing clarity in autoimmune disease management, Exagen aims to transform the lives of those affected.
Focus on Patient-Centered Care
At the heart of Exagen’s initiatives is their dedication to patient-centered care. This approach ensures that diagnostic processes and subsequent treatments are tailored to meet the unique needs of each individual. By prioritizing patient outcomes, Exagen is setting a new standard in autoimmune disease management.
Contact Information
For investors seeking more information about Exagen Inc., including insights about their innovative portfolio and future strategies, please feel free to reach out to:
Ryan Douglas
IR@exagen.com
760.560.1525
Frequently Asked Questions
What is Exagen Inc. known for?
Exagen Inc. specializes in autoimmune diagnostics, providing innovative testing solutions to improve patient care.
When are the upcoming investor conferences?
Exagen will participate in the Craig-Hallum Alpha Select Conference on November 18, 2025, and the Canaccord Genuity Forum on November 20, 2025.
What is the flagship product of Exagen?
The flagship product is AVISE CTD, which helps diagnose complex autoimmune conditions with accuracy.
How does Exagen ensure the quality of its tests?
Exagen operates a CLIA-certified and CAP-accredited laboratory to maintain high testing standards for rheumatic diseases.
What is Exagen's approach to patient care?
Exagen is dedicated to patient-centered care, focusing on personalized solutions that address the unique needs of those with autoimmune conditions.